Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Background Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and whether cross-resistance occurs is unknown. Methods Multicentre review of patients with mCRPC treated with abiraterone acetate and prednisone after progressing on enzalutamide. Primary objective was to determine abiraterone acetate response. Results Thirty patients identified from four North American centres. At abiraterone initiation, median age was 70 years (56-84 years); 70% had ECOG performance status of 0-1; all had prior docetaxel. Median prior enzalutamide treatment duration was 41 weeks (6-95 weeks), with 70% (21 of 30) having a ≥30% prostate-specific antigen (PSA) decline. Median abiraterone acetate treatment duration was 13 weeks (1-52). No objective radiographic responses were observed. Median abiraterone time to progression (PSA, objective or symptomatic) was 15.4 weeks [95% confidence interval (CI) 10.7-20.2]. Median overall survival was 50.1 weeks (95% CI 28.3-72.0). Three patients had a ≥30% PSA decline with abiraterone. Two of these patients had PSA progression as best response with prior enzalutamide. Conclusions In this study of patients progressing after enzalutamide, treatment with abiraterone was associated with a modest response rate and brief duration of effect. Primary progression on enzalutamide may not preclude a response to abiraterone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Despite frequent use in real-world settings, switching to a second ARPI after disease progression on a first-line ARPI has limited efficacy [33, 34].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [34]
Citations
Cites
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., Staffurth, J. N., North, S., Vogelzang, N. J., Saad, F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70379-0 · Cited by 1,384
Self-citationAttard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Sun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., Chen, L., Ewing, C. M., Eisenberger, M. A., Carducci, M. A., et al. (2009) · Nature Medicine · doi:10.1038/nm.1944 · Cited by 654
Mostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Richards, J., Lim, A. C., Hay, C. W., Taylor, A. E., Wingate, A., Nowakowska, K., Pezaro, C., Carreira, S., Goodall, J., Arlt, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3980 · Cited by 259
Traish, A. M., & Morgentaler, A. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605376 · Cited by 148
Parker, C. C., Heinrich, D. A., O’Sullivan, J. M., Fosså, S. D., Chodacki, A., Demkow, T., Logue, J. P., Seke, M., Widmark, A., Johannessen, D. C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.5_suppl.8 · Cited by 98
Dedifferentiation in the metastatic progression of prostate carcinoma
Cheng, L., Slezak, J. M., Bergstralh, E. J., Cheville, J. C., SWEAT, S. D., Zincke, H., & Bostwick, D. G. (1999) · Cancer · Cited by 61
Bianchini, D., Loriot, Y., Ileana, E., Sandhu, S. K., Pezaro, C., Albiges, L. K., Attard, G., Fizazi, K. S., Bono, J. S. D., & Massard, C. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)33483-9 · Cited by 3
Cited by
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 832
“reported a PSA decline $ 50% in only 1 of 30 (3%) patients treated with abiraterone after progression under enzalutamide (20).”
BackgroundProstate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, E. M., Srinivas, S., Adra, N., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H. H., D’Amico, A. V., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0050 · Cited by 596
Self-citationSartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Metadata
- Authors
- Noonan, K. L., North, S., Bitting, R. L., Armstrong, A. J., Ellard, S. L., & Chi, K. N.
- Affiliations
- BC Cancer Agency (CA)
- Cross Cancer Institute (CA)
- Duke University (US)
- Corresponding author
- Chi, K.N.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-07
- Volume
- 24
- Issue
- 7
- Pages
- 1802-1807
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2118564089
- Cited by
- 343
- References
- 16
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 9 · 2023: 4 · 2022: 14 · 2021: 18 · 2020: 11 · 2019: 18 · 2018: 30 · 2017: 34 · 2016: 45 · 2015: 61 · 2014: 62 · 2013: 24
- FWCI
- 52.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2320 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Janssen, Medivation, Sanofi aventis, Dendreon, Active Biotech/Ipsen, Imclone/Ely Lilly, BMS.
- Chi: Honoraria from Janssen and Astellas; research funding from Janssen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- abiraterone, enzalutamide, metastatic castration-resistant prostate cancer, treatment sequencing, cross-resistance, PSA response, time to progression, overall survival, androgen deprivation therapy
- MeSH terms
- Aged, Aged, 80 and over, Androstenes, Androstenols, Antineoplastic Agents, Benzamides, Bone Neoplasms, Humans, Kallikreins, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Prostatic Neoplasms, Retrospective Studies, Randomized Controlled Trials as Topic, Treatment Outcome, Prostate-Specific Antigen, Disease-Free Survival, Drug Resistance, Neoplasm, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.